Edit

The Invus Group

https://www.invus.com
Last activity: 05.11.2024
Active
Portfolio
5
Persons
4
Mentions
55
Employees: 11-50

Portfolio 5

DateNameWebsiteTotal RaisedLocation
11.07.2023@Septerna_...septerna.com$290MUnited Sta...
26.04.2023Orbital Th...orbitaltx.com$270MUnited Sta...
06.03.2023Bicara The...bicara.com$635MUnited Sta...
16.03.2017KNIMEknime.com$51.54MSwitzerlan...
15.03.2017KNIMEknime.org$21.47MSwitzerlan...

Persons 4

DateFirst NameLast NameTitleLinkedInLocation
-Christophe...MarshPrivate Eq...linkedin.c...-
-JulienMiaraPrincipallinkedin.c...-
-OlivierGueymard-linkedin.c...-
-MatthewMaslowPrincipal ...linkedin.c...-

Mentions in press and media 55

DateTitleDescription
05.11.2024PrognomiQ Raises $34M to Advance Multi-Omics Early Detection Test for Lung CancerWhat You Should Know: – PrognomiQ, a healthcare company pioneering multi-omics approaches to disease detection, has secured $34M in Series D funding led by Seer, Inc., with participation from a new strategic investor and existing investors ...
03.11.2024Vinted: Second-Hand Fashion-Focused Marketplace Company Raises Funding At €5 Billion ValuationVinted, a Europe-based leading second-hand C2C marketplace focused on fashion, announced it has closed a secondary share sale of €340 million at a valuation of €5 billion. Other major investment funds including Hedosophia, Baillie Gifford, ...
28.10.2024Agomab's $89 Million Boost: A Leap Towards Fibrosis SolutionsAgomab Therapeutics is on the rise. The Belgium-based biotech company recently secured $89 million in a Series D funding round. This infusion of capital comes from a mix of new and existing investors, including heavyweights like Sanofi and ...
28.10.2024Agomab: $89 Million (Series D) Raised For Supporting Broad Fibrosis-Focused PipelineAgomab Therapeutics announced a $89 million (€82.1 million) Series D funding round, with participation from new investors Sanofi and Invus, as well as existing investors. The proceeds from this Series D funding round will be used to further...
25.10.2024Lithuanian unicorn Vinted raises €340 million, reaches €5 billion valuationLithuanian second-hand marketplace Vinted has strengthened its position as a European leader, recently raising €340 million in a financing round led by asset manager TPG. This new funding elevates Vinted’s valuation to €5 billion, following...
25.10.2024Agomab Raises $89M in Series D FinancingAgomab Therapeutics, an Antwerp, Belgium-based biotech company developing novel treatments that aim to preserve and restore organ function in fibrotic diseases, raised $89M in Series D funding. Backers included Sanofi and Invus. Led by CEO ...
24.10.2024Vinted gains investment from TPG-led consortiumImage Courtesy: https://www.parcelandpostaltechnologyinternational.com/ At a valuation of US $ 5.39 billion, Vinted, a marketplace for secondhand clothing, has closed a secondary share sale for US $ 366.76 million. According to a press rele...
24.10.2024Vinted Secures Secondary Investment at Valuation of €5BVinted, a Vilnius, Lithuania-based second-hand C2C marketplace focused on fashion, closed a secondary share sale of €340M at a valuation of €5 Billion. The transaction, led by TPG (NASDAQ: TPG), validated Vinted’s opportunity and progress i...
22.10.2024Seaport Therapeutics: $225 Million (Series B) Raised To Advance Novel Neuropsychiatric MedicinesSeaport Therapeutics—a clinical-stage biopharmaceutical company advancing novel neuropsychiatric medicines with a proven strategy and team—announced the closing of an oversubscribed $225 million Series B financing round. General Atlantic, a...
21.10.2024Seaport Therapeutics Closes $225M Series B Financing RoundSeaport Therapeutics, a Boston, MA-based biopharmaceutical company that is developing novel neuropsychiatric medicines, raised $225M in Series B funding. The round, which brought the total amount to $325M, was led by General Atlantic, with ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In